Skip to content Skip to navigation

Journey Healing Centers speaks out against approval of new painkiller

February 14, 2012
by News release
| Reprints

Journey Healing Centers has raised its concerns over the potential approval of a new "super painkiller" called Zohydro. If Zohydro is approved, the organization claims it would represent "the first pure hydrocodone formulation on the market—a painkiller like Vicodin, Lortab and Norco, but without Tylenol or Ibuprofen mixed in."

“The number of people seeking treatment for prescription painkiller dependency at our treatment centers is growing every year and this epidemic does not appear to discriminate based on age, gender or socioeconomic status," explains Dr. Ravi Chandiramani, Journey Healing Centers Medical Director. "We see everyone from high school kids that got mixed up with the wrong crowd to corporate executives who went from seeking pain relief from a flared tennis injury to taking enough pills in one day to kill most people."

Chandiramani adds that while the drug company behind Zohydro claims it will be safer because less people will develop liver problems (and prescribers cannot authorize refills like other hydrocodone-containing drugs), many experts recognize that Zohydro could be "the next Oxycontin fiasco in the making."

In the past decade, emergency room visits related to hydrocodone abuse have increased almost 250% from 19,221 in 2000 to 86,258 in 2009, according to data compiled by the Drug Enforcement Administration (DEA). Oxycodone is now the most-abused medicine in the United States, with hydrocodone a close second, according to the DEA's annual count of drug seizures sent to police drug labs for analysis.

On top of addiction concerns, the DEA says armed robberies at pharmacies rose 81 percent between 2006 and 2010, from 380 to 686. The number of pills stolen went from 706,000 to 1.3 million. Thieves are overwhelmingly taking Oxycodone painkillers like OxyContin or Roxicodone, or hydrocodone-based painkillers like Vicodin and Norco. Both narcotics are highly addictive.

Four companies have begun patient testing on a time-released formulation containing pure hydrocodone, and one plans to apply in early 2013 to begin marketing Zohydro. This new super painkiller will be marketed to those seeking to manage moderate to severe pain, and advocates claim that this new formulation will give providers another tool in the fight against legitimate chronic pain. 

Topics

Comments

While I am no fan of Zohydro, having spent 2 lunches witheir Rep.s and leaving unimpressed, it is my opinion as a 10 yr veteran of treating dual dx patients,(chronic pain and addiction) and having Board Certification in both pain mgmt. and Addictions, that this article risks being labelled as "biased" due to assigning the label of "Super Painkiller" to this new product. Hydrocodone is among the lower in potency of all opioids, though it is certainly not by much, and misuse and deceptive marketing seems to be a problem. I agee we do not need these new opioid products approved without the abuse deterrant technology Zohydro seems to be lacking, but if the writer wants to be taken seriously as a scientific investigator , he/she should refrain from passionate labelling.

I heard about this painkiller named Zohydro. They have an awful composition and despite its strong effect on killing pain, consequences of taking them are rather harmful. I completely support Journey Hilling Center as well as http://writemyessayforcheap.blogspot.com/ in their statement that it can be used only by doctors and nurses for medical purposes.

Pages